Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Other Operating Expenses: 2021-2024

Historic Other Operating Expenses for Relay Therapeutics (RLAY) over the last 4 years, with Dec 2024 value amounting to -$13.2 million.

  • Relay Therapeutics' Other Operating Expenses fell 428.53% to -$11.4 million in Q2 2024 from the same period last year, while for Jun 2024 it was -$16.5 million, marking a year-over-year decrease of 57.83%. This contributed to the annual value of -$13.2 million for FY2024, which is 105.64% down from last year.
  • Relay Therapeutics' Other Operating Expenses amounted to -$13.2 million in FY2024, which was down 105.64% from -$6.4 million recorded in FY2023.
  • Relay Therapeutics' 5-year Other Operating Expenses high stood at $137.7 million for FY2021, and its period low was -$13.2 million during FY2024.
  • For the 3-year period, Relay Therapeutics' Other Operating Expenses averaged around -$10.4 million, with its median value being -$11.7 million (2022).
  • As far as peak fluctuations go, Relay Therapeutics' Other Operating Expenses slumped by 108.48% in 2022, and later soared by 45.00% in 2023.
  • Relay Therapeutics' Other Operating Expenses (Yearly) stood at $137.7 million in 2021, then tumbled by 108.48% to -$11.7 million in 2022, then spiked by 45.00% to -$6.4 million in 2023, then slumped by 105.64% to -$13.2 million in 2024.